General
Preferred name
Ganglioside GD2
Synonyms
P&D ID
PD143999
CAS
65988-71-8
Tags
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Ganglioside GD2 is a disialoganglioside cell adhesion molecule that is expressed on tumours of neuroectodermal origin, but which has restricted presence on normal cells. It is a drug target for neuroectoderm-derived tumours and sarcomas, including neuroblastoma, retinoblastoma, melanoma and small cell lung cancer . Two monoclonal antibodies that target GD2 have been approved for clinical use in patients with high risk neuroblastoma: (2015) and (2020). Both of these mAbs stimulate antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumour cells. (GtoPdb)
Compound Sets
1
Guide to Pharmacology
11342
External IDs
7
Properties
(calculated by RDKit )
Molecular Weight
1590.9
Hydrogen Bond Acceptors
32
Hydrogen Bond Donors
22
Rotatable Bonds
54
Ring Count
5
Aromatic Ring Count
0
cLogP
-2.05
TPSA
600.82
Fraction CSP3
0.92
Chiral centers
29.0
Largest ring
6.0
QED
0.02
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Source data